Parkinson's Disease Mechanisms and Treatments

This study shows type-I interferons drive gastrointestinal inflammation in a mouse model of Parkinson's disease, linking gut-brain pathology progression.

This study identifies novel mitochondrial gene targets in Parkinson's disease by analyzing RNA-seq data from multiple datasets and validating findings through experimental models.

This study identifies tegmental atrophy in iRBD using VBM and a novel brainstem atlas, linking atrophy in specific nuclei to autonomic dysfunction.

This study evaluates how LRRK2 coding variants affect protein function and neurotoxicity, finding that G2385R increases Rab10 phosphorylation and impairs neuronal integrity.

A survey found increased comfort and willingness among movement disorder specialists to order genetic testing for Parkinson's disease after the implementation of PD GENEration.

This study performs genetic screening of South African Parkinson's disease patients, identifying rare variants and CNVs in known PD genes, highlighting their contribution to disease in an underrepresented population.

This study investigates how age, sex, and BMI affect striatal dopamine synthesis capacity in Parkinson's disease patients and healthy controls using PET data.

This study shows that chlorogenic acid provides neuroprotection in vitro but not in vivo in a chronic Parkinson's disease mouse model.

The paper investigates the association between DNAJC13 variants and Parkinson's disease across diverse ancestries but finds no significant association.

This study shows alpha-synuclein amyloids degrade ATP and other nucleotides catalytically, contributing to energy depletion in neurodegenerative diseases.

This study conducts the first XWAS in an African cohort, identifying X chromosome variants associated with Parkinson's disease susceptibility in males and females.

This study identifies mGluR4 and Npdc1 as cell surface proteins that mediate α-synuclein fibril binding and neurodegeneration in Parkinson's disease models.

The paper examines how polygenic risk for Parkinson's disease relates to REM sleep metrics in young and late-midlife individuals, finding age-dependent associations.

The paper determines the cryo-EM structure of alpha-synuclein fibrils with the E83Q mutation, revealing structural changes linked to enhanced aggregation and pathogenicity.

This study shows that rotenone-induced Parkinsonism in mice is reversible, with full recovery of motor and non-motor deficits and dopaminergic neuron density after 12 months.

The paper shows that cortico-striatal activity decoupling occurs early in a Parkinson's Disease-like mouse model and is cell-type and behavior-specific.

This study shows that non-phosphorylated α-synuclein drives Parkinson's disease-like pathogenesis in mice, contradicting the traditional view that phosphorylated α-synuclein is pathogenic.

This study shows chronic H. pylori infection causes brain inflammation and dopaminergic neuron loss through inflammation, independent of α-synuclein pathology, and eradication reduces these effects.

The paper introduces a pathway-anchored clustering framework to analyze multimodal imaging data in Parkinson's disease, identifying stable patient clusters and structure-function associations.

This study shows that PIKfyve inhibition leads to LRRK2 hyperactivation through PI3P and CASM, revealing a new mechanism involving membrane lipids and Rab proteins.

This paper develops a human gut organoid model incorporating PD-relevant cell types to study gut-brain pathways in Parkinson disease.

This study identifies GPNMB as a biomarker for lysosomal dysfunction and shows it is secreted via LRRK2-modulated lysosomal exocytosis in macrophages.

This paper identifies GSDME as a mediator of neurodegeneration in Parkinson's disease by linking mitochondrial damage to pyroptotic cell death through caspase-3 activation.

This study investigates how phosphorylation of α-synuclein at S129 affects DNAJB1 binding to fibrils using biochemical assays and solid-state NMR.

This study examines bioenergetic and protein processing defects in iPSC-derived dopamine neurons from idiopathic Parkinson's disease patients, revealing impaired mitochondrial function and alpha synuclein aggregation.

This paper investigates the association between chlorpyrifos exposure and Parkinson's disease risk, finding increased odds of PD with long-term exposure and demonstrating causal mechanisms in animal models.

This paper identifies Epoxyazadiradione as a compound that improves Parkinson's disease symptoms in mice by enhancing heat shock factor 1 and protein degradation pathways without affecting redox balance.

The paper investigates the role of STING in Parkinson's disease by comparing motor behavior and brain pathology in STING-deficient and wild-type mice exposed to alpha-synuclein fibrils.

This study identifies mTOR pathway deregulation in fibroblasts from LRRK2 Parkinson's patients through proteomic and phospho-proteomic analysis.

This study shows that electroconvulsive therapy (ECT) improves motor function in Parkinsonian mice by promoting dopaminergic axon regeneration and restoring striatal circuitry.